Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Hoffman

Showing results (171-180 of 204) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FBrady L Stein, Stephen T Oh, Dmitriy Berenzon, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
The reparative immunologic consequences of stem cell transplantation as a cellular therapy for refractory Crohn's diseaseDaniela Guisado, Sayali Talware, Xiaoli Wang, et al.
Gut|February 17, 2025
Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's diseaseDaniela Guisado, Sayali Talware, Xiaoli Wang, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Linezolid Acts as a Selective Inhibitor of the JAK2 <sup>V617F</sup> MutationAnisa Azatovna Gumerova, Christoph Schaniel, Zixing Huang, et al.
Blood|May 10, 2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelAyalew Tefferi, Juergen Thiele, Attilio Orazi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 12, 2018
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 StudyVikas Gupta, Heidi E Kosiorek, Adam Mead, et al.
The New England Journal of Medicine|February 21, 2024
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia VeraMarina Kremyanskaya, Andrew T Kuykendall, Naveen Pemmaraju, et al.
Blood Advances|November 20, 2020
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlinBridget K Marcellino, Noushin Farnoud, Bruno Cassinat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetTiziano Barbui, Giovanni Barosi, Gunnar Birgegard, et al.
Pageof 21

Showing results (171-180 of 204) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FBrady L Stein, Stephen T Oh, Dmitriy Berenzon, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
The reparative immunologic consequences of stem cell transplantation as a cellular therapy for refractory Crohn's diseaseDaniela Guisado, Sayali Talware, Xiaoli Wang, et al.
Gut|February 17, 2025
Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's diseaseDaniela Guisado, Sayali Talware, Xiaoli Wang, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Linezolid Acts as a Selective Inhibitor of the JAK2 <sup>V617F</sup> MutationAnisa Azatovna Gumerova, Christoph Schaniel, Zixing Huang, et al.
Blood|May 10, 2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelAyalew Tefferi, Juergen Thiele, Attilio Orazi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 12, 2018
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 StudyVikas Gupta, Heidi E Kosiorek, Adam Mead, et al.
The New England Journal of Medicine|February 21, 2024
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia VeraMarina Kremyanskaya, Andrew T Kuykendall, Naveen Pemmaraju, et al.
Blood Advances|November 20, 2020
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlinBridget K Marcellino, Noushin Farnoud, Bruno Cassinat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetTiziano Barbui, Giovanni Barosi, Gunnar Birgegard, et al.
Pageof 21